Overview

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Phase:
PHASE3
Details
Lead Sponsor:
Incyte Corporation